Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01294228 · ClinicalTrials.gov registry record

Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU

A clinical trial, sponsored by Abbott RDx Cardiometabolic.

Completed
Registry status
1,001
Enrollment target

NCT01294228 is a clinical trial that has completed, run by Abbott RDx Cardiometabolic. The registered enrollment target is 1,001 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01294228 has completed, sponsored by Abbott RDx Cardiometabolic.

COMPLETED
Registry status
1,001 participants
Enrollment target

Study Summary

This is a multi-center, prospective, observational study of patients that are admitted to the intensive care unit (ICU). This study does not include any treatment or intervention and it is considered Nonsignificant Risk.

Trial Details

FieldValue
Enrollment Target 1,001 participants
Start Date 2011-03
Est. Completion 2014-12

Sponsor

Abbott RDx Cardiometabolic

14 total trials

What the Registry Record Tells You About NCT01294228

The ClinicalTrials.gov registry entry for NCT01294228 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,001 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott RDx Cardiometabolic, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01294228 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01294228 about?

NCT01294228 is a clinical study titled "Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU". This is a multi-center, prospective, observational study of patients that are admitted to the intensive care unit (ICU). This study does not include any treatment or intervention and it is considered Nonsignificant Risk.

What is the current status of trial NCT01294228?

This trial is currently completed. The enrollment target is 1,001 participants. The study started on 2011-03. Estimated completion is 2014-12.

Who is sponsoring clinical trial NCT01294228?

This trial is sponsored by Abbott RDx Cardiometabolic, which has 14 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.